Inhalational steroids and iatrogenic Cushing's syndrome
Open accessThe DOI matches its Crossref record; 104 of the 104 references it cites were found in a registry or an index.
Abstract
Bronchial asthma (BA) and Allergic rhinitis (AR) are common clinical problems encountered in day to day practice, where inhalational corticosteroids (ICS) or intranasal steroids (INS) are the mainstay of treatment. Iatrogenic Cushing syndrome (CS) is a well known complication of systemic steroid administration. ICS /INS were earlier thought to be safe, but now more and more number of case reports of Iatrogenic Cushing syndrome have been reported, especially in those who are taking cytochrome P450 (CYP 450) inhibitors. Comparing to the classical clinical features of spontaneous Cushing syndrome, iatrogenic Cushing syndrome is more commonly associated with osteoporosis, increase in intra-ocular pressure, benign intracranial hypertension, aseptic necrosis of femoral head and pancreatitis, where as hypertension, hirsuitisum and menstrual irregularities are less common. Endocrine work up shows low serum cortisol level with evidence of HPA (hypothalamo-pituitary-adrenal) axis suppression. In all patients with features of Cushing syndrome with evidence of adrenal suppression always suspect iatrogenic CS. Since concomitant administration of cytochrome P450 inhibitors in patients on ICS/INS can precipitate iatrogenic CS, avoidance of CYP450 inhibitors, its dose reduction or substitution of ICS are the available options. Along with those, measures to prevent the precipitation of adrenal crisis has to be taken. An update on ICS-/INS- associated iatrogenic CS and its management is presented here.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Of note, among all inhaled glucocorticoids fluticasone propionate is most frequently associated with the development of symptomatic glucocorticoid-induced adrenal insufficiency and exogenous Cushing syndrome (100, 104, 107-111).”
From European Society of Endocrinology and Endocrine Society Joint Clinical Guideline: Diagnosis and Therapy of Glucocorticoid-induced Adrenal Insufficiency (2024) · cites this paper as [107]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Allergic Rhinitis and its Impact on Asthma (ARIA) 2008*
Bousquet, J., Khaltaev, N., Cruz, A. A., Denburg, J., Fokkens, W. J., Togias, A., Zuberbier, T., Baena‐Cagnani, C. E., Canonica, G. W., Van Weel, C., et al. (2008) · Allergy · doi:10.1111/j.1398-9995.2007.01620.x · Cited by 4,729
Antiinflammatory Action of Glucocorticoids — New Mechanisms for Old Drugs
Rhen, T., & Cidlowski, J. A. (2005) · New England Journal of Medicine · doi:10.1056/nejmra050541 · Cited by 3,149 · cited 1×
“The clinical efficacy of INC is because of its antiinflammatory effects [45].”
BackgroundLacroix, A., Feelders, R. A., Stratakis, C. A., & Nieman, L. K. (2015) · The Lancet · doi:10.1016/s0140-6736(14)61375-1 · Cited by 1,777
Use of Inhaled Corticosteroids and Risk of Fractures
Van Staa, T. P., Leufkens, H. G. M., & Cooper, C. (2001) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.2001.16.3.581 · Cited by 1,308
Liu, D., Ahmet, A., Ward, L., Krishnamoorthy, P., Mandelcorn, E. D., Leigh, R., Brown, J. P., Cohen, A., & Kim, H. (2013) · Allergy, Asthma & Clinical Immunology · doi:10.1186/1710-1492-9-30 · Cited by 1,268 · cited 1×
“But some features, such as an increase in intraocular pressure, benign intracranial hypertension, cataracts, osteoporosis, aseptic necrosis of the femoral head, and pancreatitis, are more common in iatrogenic than endogenous CS, whereas features like hypertension, hirsutism, and oligomenorrhea/amenorrhea are less prev…”
BackgroundNewell-Price, J., Bertagna, X., Grossman, A. B., & Nieman, L. K. (2006) · The Lancet · doi:10.1016/s0140-6736(06)68699-6 · Cited by 1,165 · cited 1×
“Cushing syndrome (CS) is a group of clinical features caused by hypercortisolism [56].”
BackgroundLow-Dose Inhaled Corticosteroids and the Prevention of Death from Asthma
Suissa, S., Ernst, P., Benayoun, S., Baltzan, M., & Cai, B. (2000) · New England Journal of Medicine · doi:10.1056/nejm200008033430504 · Cited by 1,100 · cited 1×
“Various clinical trials proved that ICS in Bronchial asthma significantly reduce the inflammation and hyperresponsiveness of airways, thereby improving lung function, decreasing the severity of symptoms and occurrence of acute exacerbation [5, 6].”
BackgroundBafadhel, M., McKenna, S., Terry, S., Mistry, V., Reid, C., Haldar, P., McCormick, M., Haldar, K., Kebadze, T., Duvoix, A., et al. (2011) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201104-0597oc · Cited by 1,094
Qaseem, A., Wilt, T. J., Weinberger, S. E., Hanania, N. A., Criner, G., van der Molen, T., Marciniuk, D. D., Denberg, T., Schünemann, H., Wedzicha, W., et al. (2011) · Annals of Internal Medicine · doi:10.7326/0003-4819-155-3-201108020-00008 · Cited by 1,087 · cited 1×
“Chronic obstructive pulmonary disease (COPD) is characterized by air flow limitation that is not fully reversible, in contrast to bronchial asthma, which is associated with reversible airway obstruction due to airway hyper-responsiveness and inflammation [10, 11].”
BackgroundNontraumatic Necrosis of Bone (Osteonecrosis)
Desforges, J. F., & Mankin, H. J. (1992) · New England Journal of Medicine · doi:10.1056/nejm199205283262206 · Cited by 958 · cited 1×
“But some features, such as an increase in intraocular pressure, benign intracranial hypertension, cataracts, osteoporosis, aseptic necrosis of the femoral head, and pancreatitis, are more common in iatrogenic than endogenous CS, whereas features like hypertension, hirsutism, and oligomenorrhea/amenorrhea are less prev…”
BackgroundSystemic Adverse Effects of Inhaled Corticosteroid Therapy: A Systematic Review and Meta-analysis
Lipworth, B. J. (1999) · Archives of Internal Medicine · doi:10.1001/archinte.159.9.941 · Cited by 918 · cited 1×
“Use of ICS are associated with increased risk of pneumonia, tuberculosis, easy bruising, osteoporosis, diabetes, oro-pharyngeal candidiasis, hoarseness of voice and even iatrogenic CS in patients with COPD, where the risk-benefit ratio has to be considered before starting steroids [17-24].”
BackgroundCushing, H. (1964) · Journal of Neurosurgery · doi:10.3171/jns.1964.21.4.0318 · Cited by 851 · cited 1×
“CS takes its name from Harvey Cushing who, in 1912, first reported a patient with features of hypercorticolism [57].”
BackgroundThe Cytochrome P450 Superfamily: Biochemistry, Evolution and Drug Metabolism in Humans
P.B. Danielson, B. S. P. (2002) · Current Drug Metabolism · doi:10.2174/1389200023337054 · Cited by 772 · cited 2×
“system, mainly by the iso-enzyme cytochrome P450 3A4 (CYP3A4) [51].”
BackgroundAllergic Rhinitis and its Impact on Asthma (ARIA)
Bousquet, J. (2003) · Clinical & Experimental Allergy Reviews · doi:10.1046/j.1472-9725.2003.00063.x · Cited by 734
Regional Lung Deposition and Bronchodilator Response as a Function of β 2 -Agonist Particle Size
Usmani, O. S., Biddiscombe, M. F., & Barnes, P. J. (2005) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200410-1414oc · Cited by 578 · cited 1×
“Making average diameter of aerosol smaller reduces the amount of oro-pharyngeal deposition of the drug, and increases the alveolar deposition [28, 29].”
BackgroundCushing's syndrome in children and adolescents. Presentation, diagnosis, and therapy.
Magiakou, M. A., Mastorakos, G., Oldfield, E. H., Gomez, M. T., Doppman, J. L., Cutler, G. B., Nieman, L. K., & Chrousos, G. P. (1994) · New England Journal of Medicine · doi:10.1056/nejm199409083311002 · Cited by 430 · cited 1×
“In paediatric CS generalized obesity is seen, in contrast to adult CS which is associated with central obesity [77].”
BackgroundQaseem, A., Snow, V., Shekelle, P., Sherif, K., Wilt, T. J., Weinberger, S., Owens, D. K., & for the Clinical Efficacy Assessment Subcommittee of the American College of Physicians* (2007) · Annals of Internal Medicine · doi:10.7326/0003-4819-147-9-200711060-00008 · Cited by 424
ROSS, E. (1982) · The Lancet · doi:10.1016/s0140-6736(82)92749-0 · Cited by 390 · cited 1×
“Few features of Cushing’s syndrome have more discriminatory value than others, which includes reddish purple striae, proximal muscle, weakness, plethora, bruising with no obvious trauma, and unexplained osteoporosis [75].”
BackgroundErnst, P., Gonzalez, A. V., Brassard, P., & Suissa, S. (2007) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200611-1630oc · Cited by 389 · cited 1×
“Use of ICS are associated with increased risk of pneumonia, tuberculosis, easy bruising, osteoporosis, diabetes, oro-pharyngeal candidiasis, hoarseness of voice and even iatrogenic CS in patients with COPD, where the risk-benefit ratio has to be considered before starting steroids [17-24].”
BackgroundHow Do Corticosteroids Work in Asthma?
Barnes, P. J., & Adcock, I. M. (2003) · Annals of Internal Medicine · doi:10.7326/0003-4819-139-5_part_1-200309020-00012 · Cited by 371 · cited 1×
“Corticosteroids interfere with the various pathways involved in the process of airway inflammation in BA, by binding to specific DNA sequences [7].”
BackgroundCANDIA, S. D. (1951) · PubMed · Cited by 365
Inhaled Corticosteroids and the Risks of Diabetes Onset and Progression
Suissa, S., Kezouh, A., & Ernst, P. (2010) · The American Journal of Medicine · doi:10.1016/j.amjmed.2010.06.019 · Cited by 317 · cited 1×
“Use of ICS are associated with increased risk of pneumonia, tuberculosis, easy bruising, osteoporosis, diabetes, oro-pharyngeal candidiasis, hoarseness of voice and even iatrogenic CS in patients with COPD, where the risk-benefit ratio has to be considered before starting steroids [17-24].”
BackgroundEffects of inhaled glucocorticoids on bone density in premenopausal women.
Israel, E., Banerjee, T. R., Fitzmaurice, G. M., Kotlov, T. V., LaHive, K., & LeBoff, M. S. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa002304 · Cited by 303 · cited 1×
“But some features, such as an increase in intraocular pressure, benign intracranial hypertension, cataracts, osteoporosis, aseptic necrosis of the femoral head, and pancreatitis, are more common in iatrogenic than endogenous CS, whereas features like hypertension, hirsutism, and oligomenorrhea/amenorrhea are less prev…”
BackgroundOccult Cushing’s syndrome in type-2 diabetes
Catargi, B., Rigalleau, V., Poussin, A., Ronci-Chaix, N., Bex, V., Vergnot, V., Gin, H., Roger, P., & Tabarin, A. (2003) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2003-030254 · Cited by 287 · cited 1×
“Glucose intolerance is common and frank diabetes can be seen in some cases, especially in patients with a family history of type 2 diabetes mellitus [69].”
BackgroundHigh cardiovascular risk in patients with Cushing’s syndrome according to 1999 WHO/ISH guidelines
Mancini, T., Kola, B., Mantero, F., Boscaro, M., & Arnaldi, G. (2004) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2004.02168.x · Cited by 278 · cited 1×
“Cardiovascular events are also more common in patients with CS, there by increasing the morbidity and mortality [73].”
BackgroundHutter, A. M., & Kayhoe, D. E. (1966) · The American Journal of Medicine · doi:10.1016/0002-9343(66)90219-1 · Cited by 276
The Glucocorticoid Receptor: Coding a Diversity of Proteins and Responses through a Single Gene
Yudt, M. R., & Cidlowski, J. A. (2002) · Molecular Endocrinology · doi:10.1210/me.2002-0106 · Cited by 275 · cited 1×
“alteration in gene transcription and protein synthesis, resulting in reduction of airway inflammation, by reducing the production of various inflammatory mediators from cells like macrophages, eosinophils, lymphocytes, mast cells and dendritic cells [8, 9].”
BackgroundFelson, D., & Anderson, J. (1987) · The Lancet · doi:10.1016/s0140-6736(87)92870-4 · Cited by 267 · cited 1×
“Avascular necrosis of the femoral head occurs more commonly in patients with exogenous CS [68].”
BackgroundLoke, Y. K., Cavallazzi, R., & Singh, S. (2011) · Thorax · doi:10.1136/thx.2011.160028 · Cited by 267 · cited 1×
“Use of ICS are associated with increased risk of pneumonia, tuberculosis, easy bruising, osteoporosis, diabetes, oro-pharyngeal candidiasis, hoarseness of voice and even iatrogenic CS in patients with COPD, where the risk-benefit ratio has to be considered before starting steroids [17-24].”
BackgroundRelevance of pharmacokinetics and pharmacodynamics of inhaled corticosteroids to asthma
Derendorf, H., Nave, R., Drollmann, A., Cerasoli, F., & Wurst, W. (2006) · European Respiratory Journal · doi:10.1183/09031936.00074905 · Cited by 253 · cited 1×
“Ciclesonide and beclomethasone are having greatest lung deposition [33].”
BackgroundDerendorf, H., & Meltzer, E. O. (2008) · Allergy · doi:10.1111/j.1398-9995.2008.01750.x · Cited by 233 · cited 1×
“furoate, fluticasone propionate, mometasone furoate, and triamcinolone acetonide [44].”
BackgroundExogenous cushing’s syndrome and glucocorticoid withdrawal
Hopkins, R. L., & Leinung, M. C. (2005) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2005.01.013 · Cited by 224 · cited 1×
“Cushing’s syndrome due to exogenous steroid administration is variably described as exogenous Cushing’s, steroidinduced Cushing’s or iatrogenic CS [59].”
BackgroundEpidemiology of Cushing’s Syndrome
Steffensen, C., Bak, A. M., Zøylner Rubeck, K., & Jørgensen, J. O. L. (2010) · Neuroendocrinology · doi:10.1159/000314297 · Cited by 217 · cited 1×
“The pulmonary residence time (PRT) is the average time required for absorption of the molecules in to the systemic circulation after getting deposited in the lung [38].”
BackgroundPharmacokinetics and pharmacodynamics of inhaled corticosteroids
Derendorf, H., Hochhaus, G., Meibohm, B., Möllmann, H., & Barth, J. (1998) · Journal of Allergy and Clinical Immunology · doi:10.1016/s0091-6749(98)70156-3 · Cited by 216 · cited 1×
“Use of various delivery systems for inhaled corticosteroids results in high amount of oro-pharyngeal deposition of the drug (up to 80% with pressurized metered-dose inhalers [MDI] and dry powder inhalers) that is subsequently swallowed, absorbed from GIT, undergo first-pass metabolism in the liver, and reaches the sys…”
BackgroundNilsson, I. M., & Holmberg, L. (1974) · The Lancet · doi:10.1016/s0140-6736(74)91962-x · Cited by 212
HIV Protease Inhibitor-Related Lipodystrophy Syndrome
Carr, A. (2000) · Clinical Infectious Diseases · doi:10.1086/313854 · Cited by 210 · cited 1×
“Lipodystrophy is a slow, chronic change of fat distribution, usually evolving over many years, compared to rapid evolution in iatrogenic CS [90].”
BackgroundMultiple Factors Contribute to the Pathogenesis of Hypertension in Cushing's Syndrome
SARUTA, T., SUZUKI, H., HANDA, M., IGARASHI, Y., KONDO, K., & SENBA, S. (1986) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-62-2-275 · Cited by 207 · cited 1×
“The mechanisms include mineralocorticoid effects of cortisol, the action of cortisol on peripheral and systemic vasculature, and activation of the renin-angiotensin system [70, 71].”
BackgroundAssociation of Inhaled Corticosteroid Use With Cataract Extraction in Elderly Patients
Garbe, E. (1998) · JAMA · doi:10.1001/jama.280.6.539 · Cited by 201 · cited 1×
“Use of ICS are associated with increased risk of pneumonia, tuberculosis, easy bruising, osteoporosis, diabetes, oro-pharyngeal candidiasis, hoarseness of voice and even iatrogenic CS in patients with COPD, where the risk-benefit ratio has to be considered before starting steroids [17-24].”
BackgroundGlucocorticoid-induced adrenal insufficiency
Krasner, A. S. (1999) · JAMA · doi:10.1001/jama.282.7.671 · Cited by 197 · cited 1×
“Iatrogenic CS is usually associated with evidence of Adrenal insufficiency [98, 99].”
BackgroundWhat causes steroid cataracts? A review of steroid‐induced posterior subcapsular cataracts
Jobling, A. I., & Augusteyn, R. C. (2002) · Clinical and Experimental Optometry · doi:10.1111/j.1444-0938.2002.tb03011.x · Cited by 177 · cited 1×
“But some features, such as an increase in intraocular pressure, benign intracranial hypertension, cataracts, osteoporosis, aseptic necrosis of the femoral head, and pancreatitis, are more common in iatrogenic than endogenous CS, whereas features like hypertension, hirsutism, and oligomenorrhea/amenorrhea are less prev…”
BackgroundSoffer, L. J., Iannaccone, A., & Gabrilove, J. L. (1961) · The American Journal of Medicine · doi:10.1016/0002-9343(61)90069-9 · Cited by 176
The Influence of Lung Deposition on Clinical Response
Pritchard, J. N. (2001) · Journal of Aerosol Medicine · doi:10.1089/08942680150506303 · Cited by 176 · cited 1×
“Various factors influence the pulmonary deposition of ICS [32].”
BackgroundFoisy, M., Yakiwchuk, E., Chiu, I., & Singh, A. (2008) · HIV Medicine · doi:10.1111/j.1468-1293.2008.00579.x · Cited by 174 · cited 1×
“substituting the inhaled/intranasal corticosteroid with another corticosteroid with less potential for drug interactions and (4) use the lowest possible dose of ICS/INC along with CYP3A4 isozyme inhibitors, if both has to be continued depending upon the clinical condition [96].”
MethodTORPY, D. J., MULLEN, N., ILIAS, I., & NIEMAN, L. K. (2002) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2002.tb04419.x · Cited by 173 · cited 11×
“Increased ACTH induces hyper-pigmentation, and it is not by excess cortisol.”
BackgroundInfluentialWajchenberg, B. L. (1995) · Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.80.9.2791 · Cited by 171 · cited 1×
“The most common feature of Cushing's syndrome is progressive central (centripetal) obesity, which usually involves the face, neck, trunk, abdomen and, internally, spinal canal and mediastinum [61].”
BackgroundPotential Adverse Effects of the Inhaled Corticosteroids
Kelly, H. (2003) · Journal of Allergy and Clinical Immunology · doi:10.1016/s0091-6749(03)00002-2 · Cited by 171
Bender, B. G., Leung, S. B., & Leung, D. Y. M. (2003) · Journal of Allergy and Clinical Immunology · doi:10.1067/mai.2003.174 · Cited by 169
Risk-to-benefit ratio of inhaled corticosteroids in patients with COPD
Price, D., Yawn, B., Brusselle, G., & Rossi, A. (2012) · Primary Care Respiratory Journal · doi:10.4104/pcrj.2012.00092 · Cited by 169 · cited 1×
“1874-3064/14 2014 Bentham Open Keywords: Allergic rhinitis (AR), bronchial asthma (BA), chronic obstructive pulmonary disease (COPD), Cushing syndrome (CS), HPA (hypothalamo-pituitary-adrenal) axis, inhalational corticosteroids (ICS), intranasal steroids (INS).”
BackgroundLado-Abeal, J. (1998) · Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.83.9.3083 · Cited by 161
Review of the Molecular and Cellular Mechanisms of Action of Glucocorticoids for Use in Asthma
Umland, S. P., Schleimer, R. P., & Johnston, S. L. (2002) · Pulmonary Pharmacology & Therapeutics · doi:10.1006/pupt.2001.0312 · Cited by 159 · cited 1×
“alteration in gene transcription and protein synthesis, resulting in reduction of airway inflammation, by reducing the production of various inflammatory mediators from cells like macrophages, eosinophils, lymphocytes, mast cells and dendritic cells [8, 9].”
BackgroundThe definition and diagnosis of Asthma
Hargreave, F. E., & Nair, P. (2009) · Clinical & Experimental Allergy · doi:10.1111/j.1365-2222.2009.03321.x · Cited by 159
Effect of Fluticasone in Severe Polyposis
Lund, V. J., Flood, J., Sykes, A. P., & Richards, D. H. (1998) · Archives of Otolaryngology–Head & Neck Surgery · doi:10.1001/archotol.124.5.513 · Cited by 159
Inhaled Corticosteroids and the Prevention of Readmission to Hospital for Asthma
BLAIS, L., ERNST, P., BOIVIN, J.-F., & SUISSA, S. (1998) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.158.1.9707107 · Cited by 157 · cited 1×
“Various clinical trials proved that ICS in Bronchial asthma significantly reduce the inflammation and hyperresponsiveness of airways, thereby improving lung function, decreasing the severity of symptoms and occurrence of acute exacerbation [5, 6].”
BackgroundEfficacy and safety of mometasone furoate nasal spray in nasal polyposis
Small, C. B., Hernandez, J., Reyes, A., Schenkel, E. J., Damiano, A., Stryszak, P., Staudinger, H. W., & Danzig, M. R. (2005) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2005.07.027 · Cited by 154 · cited 1×
“Use of INC reduces the polyp size as well as the nasal symptoms, including nasal congestion, sneezing, rhinorrheoa, loss of smell, and postnasal drip in patients with chronic rhino-sinusitis with nasal polyps [46, 47].”
BackgroundGuignat, L., BERTAGNA, X. Y., & Bertherat, J. Y. (2008) · PubMed · Cited by 149
Inactivity Amplifies the Catabolic Response of Skeletal Muscle to Cortisol
FERRANDO, A. A. (1999) · Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.84.10.3515 · Cited by 144 · cited 1×
“Proximal muscle wasting and weakness are common in CS, due to the catabolic effects of excess glucocorticoids on skeletal muscle, and are not seen in patients with pseudoCushing's syndrome [66].”
BackgroundMiller‐Larsson, A., Mattsson, H., Hjertberg, E., Dahlbäck, M., Tunek, A., & Brattsand, R. (1998) · PubMed · Cited by 143
Inhaled corticosteroids in COPD: the case against: Fig. 1—
Suissa, S., & Barnes, P. J. (2009) · European Respiratory Journal · doi:10.1183/09031936.00190908 · Cited by 141 · cited 1×
“In bronchial asthma ICS is the mainstay of treatment but in COPD, its role is still controversial [12].”
BackgroundA systematic review of the use of intranasal steroids in the treatment of chronic rhinosinusitis
Joe, S. A., Thambi, R., & Huang, J. (2008) · Otolaryngology–Head and Neck Surgery · doi:10.1016/j.otohns.2008.05.628 · Cited by 136 · cited 2×
“once-daily dosing of m ny of the INC [49,50].”
BackgroundSamaras, K., Pett, S., Gowers, A., McMurchie, M., & Cooper, D. A. (2005) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2005-0036 · Cited by 133 · cited 1×
“Because of its potent hepatic CYP3A4 iso-enzyme inhibitory property, ritonavir and other PIs can result in various drug– drug interactions [55].”
BackgroundInhaled Corticosteroids and Risk of Tuberculosis in Patients with Respiratory Diseases
Brassard, P., Suissa, S., Kezouh, A., & Ernst, P. (2010) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201007-1099oc · Cited by 132 · cited 1×
“Use of ICS are associated with increased risk of pneumonia, tuberculosis, easy bruising, osteoporosis, diabetes, oro-pharyngeal candidiasis, hoarseness of voice and even iatrogenic CS in patients with COPD, where the risk-benefit ratio has to be considered before starting steroids [17-24].”
BackgroundTempark, T., Phatarakijnirund, V., Chatproedprai, S., Watcharasindhu, S., Supornsilchai, V., & Wananukul, S. (2010) · Endocrine · doi:10.1007/s12020-010-9393-6 · Cited by 131 · cited 1×
“The most valuable laboratory test is the detection of synthetic glucocorticoids in the urine by highpressure liquid chromatography [93, 94].”
BackgroundScreening and diagnosis of Cushing’s syndrome
Findling, J. W., & Raff, H. (2005) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2005.02.001 · Cited by 127
Psychiatric aspects of Cushing's syndrome
Kelly, W. F. (1996) · QJM · doi:10.1093/qjmed/89.7.543 · Cited by 119 · cited 1×
“Common psychiatric abnormalities include agitated depression, lethargy, paranoia, overt psychosis, insomnia, emotional lability, irritability, anxiety and panic attacks [65].”
BackgroundIntranasal steroid sprays in the treatment of rhinitis: is one better than another?
Waddell, A. N., Patel, S. K., Toma, A. G., & Maw, A. R. (2003) · The Journal of Laryngology & Otology · doi:10.1258/002221503322542818 · Cited by 108 · cited 2×
“once-daily dosing of m ny of the INC [49,50].”
BackgroundPopulation Pharmacokinetics and Pharmacodynamics of Ciclesonide
Rohatagi, S., Arya, V., Zech, K., Nave, R., Hochhaus, G., Jensen, B. K., & Barrett, J. S. (2003) · The Journal of Clinical Pharmacology · doi:10.1177/0091270002250998 · Cited by 105 · cited 1×
“(99%) their systemic side-effects and adrenal suppression are minimal [36, 37].”
BackgroundPharmacokinetics of intranasal corticosteroids
Szefler, S. J. (2001) · Journal of Allergy and Clinical Immunology · doi:10.1067/mai.2001.115563 · Cited by 102 · cited 1×
“The more lipophilic newer compounds like fluticasone propionate, and mometasone furoate, undergo rapid and extensive first-pass metabolism leading to negligible systemic absorption [48].”
BackgroundComparison of Inhaled Corticosteroids: An Update
Kelly, H. W. (2009) · Annals of Pharmacotherapy · doi:10.1345/aph.1l546 · Cited by 101 · cited 1×
“The dose of inhaled steroid is much lower than the oral dose (ratio 1:20) required to achieve the same therapeutic effects [4].”
BackgroundCushing’s Syndrome: All Variants, Detection, and Treatment
Sharma, S. T., & Nieman, L. K. (2011) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2011.01.006 · Cited by 89 · cited 1×
“The mechanisms include mineralocorticoid effects of cortisol, the action of cortisol on peripheral and systemic vasculature, and activation of the renin-angiotensin system [70, 71].”
BackgroundMountjoy, K. G. (1994) · Molecular and Cellular Endocrinology · doi:10.1016/0303-7207(94)90113-9 · Cited by 87 · cited 2×
“In humans ACTH is the principal hormone which induces pigmentation, and it acts via binding to melanocyte-stimulating hormone receptors [62].”
BackgroundCushing’s Syndrome in Children and Adolescents
Mastorakos, G. P., & Kanaka‐Gantenbein, C. (2005) · Springer eBooks · doi:10.1007/3-540-26861-8_9 · Cited by 84
Prolonged Airway Activity and Improved Selectivity of Budesonide Possibly Due to Esterification
Miller‐Larsson, A., Jansson, P., Runström, A., & Brattsand, R. (2000) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.162.4.9806112 · Cited by 83 · cited 1×
“The lipid conjugation or fatty acid esterification is the process by which ICS form a reversible chemical bond with the fatty acid in the pulmonary tissue [40].”
BackgroundSmall airways: an important but neglected target in the treatment of obstructive airway diseases
Sturton, G., Persson, C. G. A., & Barnes, P. J. (2008) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2008.04.003 · Cited by 80 · cited 1×
“Making average diameter of aerosol smaller reduces the amount of oro-pharyngeal deposition of the drug, and increases the alveolar deposition [28, 29].”
BackgroundGlucocorticoids and Osteoporosis
Adler, R. A., & Rosen, C. J. (1994) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/s0889-8529(18)30090-2 · Cited by 79
Rohatagi, S., Luo, Y., Shen, L., Guo, Z., Schemm, C., Huang, Y., Chen, K. S., David, M., Nave, R., & King, S. P. (2005) · PubMed · Cited by 78
Ciclesonide: An On-Site-Activated Steroid
Dietzel, K., Engelst�tter, R., & Keller, A. (2001) · KARGER eBooks · doi:10.1159/000062132 · Cited by 75 · cited 1×
“ICS are also directly absorbed from the lung after deposition in the respiratory tract following inhalation [27].”
BackgroundAdams, N., & Jones, P. M. (2006) · Respiratory Medicine · doi:10.1016/j.rmed.2006.04.015 · Cited by 74 · cited 1×
“The commonly available ICS are beclomethasone, budesonide, fluticasone, flunisolide, mometasone, triamcinolone, ciclesonide and budesonide [30].”
BackgroundSkin Manifestations of Inhaled Corticosteroids in COPD Patients
Tashkin, D. P., Murray, H. E., Skeans, M. A., & Murray, R. P. (2004) · CHEST Journal · doi:10.1016/s0012-3692(15)31287-3 · Cited by 62 · cited 1×
“Use of ICS are associated with increased risk of pneumonia, tuberculosis, easy bruising, osteoporosis, diabetes, oro-pharyngeal candidiasis, hoarseness of voice and even iatrogenic CS in patients with COPD, where the risk-benefit ratio has to be considered before starting steroids [17-24].”
BackgroundIntranasal Corticosteroids and Adrenal Suppression
Bruni, F. M., Luca, G. D., Venturoli, V., & Boner, A. L. (2009) · NeuroImmunoModulation · doi:10.1159/000216193 · Cited by 58 · cited 1×
“The most valuable laboratory test is the detection of synthetic glucocorticoids in the urine by highpressure liquid chromatography [93, 94].”
BackgroundInhaled Corticosteroids in Chronic Obstructive Pulmonary Disease
Suissa, S., McGhan, R. M., Niewoehner, D. E., & Make, B. J. (2007) · Proceedings of the American Thoracic Society · doi:10.1513/pats.200701-024fm · Cited by 57
Kedem, E., Shahar, E., Hassoun, G., & Pollack, S. (2010) · Journal of Asthma · doi:10.3109/02770903.2010.485666 · Cited by 56 · cited 1×
“In iatrogenic CS, the exogenous steroids suppress HPA axis resulting in decreased production of cortisol.”
BackgroundWhy Particle Size Should Affect Clinical Response to Inhaled Therapy
Howarth, P. H. (2001) · Journal of Aerosol Medicine · doi:10.1089/08942680150506312 · Cited by 55 · cited 1×
“If the particle size of ICS is between 1-5 μm, they are deposited in the bronchi and bronchioles more likely, where as particle size of >5 μm are more likely deposited in the oropharayngal cavity, and very small particles (<1 μm) are either deposited in the upper airways or exhaled out [34].”
BackgroundWachter, E. D., Malfroot, A., Schutter, I. D., Vanbesien, J., & Schepper, J. D. (2003) · Journal of Cystic Fibrosis · doi:10.1016/s1569-1993(03)00022-5 · Cited by 52 · cited 1×
“cytochrome P450, making this as a better choice in patients requiring inhaled therapy, while on a cytochrome P450 inhibitor [53, 54].”
BackgroundKaplan, J. G., Barasch, E., Hirschfeld, A. D., Ross, L. F., Einberg, K., & Gordon, M. (1989) · Neurology · doi:10.1212/wnl.39.8.1031 · Cited by 52
Tirabassi, G., Papa, R., Faloia, E., Boscaro, M., & Arnaldi, G. (2011) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2011.04096.x · Cited by 50 · cited 1×
“So there may be hypercortisolism, abnormal dexamethasone suppressibility and mild elevation of urinary free cortisol (UFC), causing diagnostic confusion with true CS, and is called Pseudo-Cushing’s syndrome [91].”
BackgroundDrug interactions between inhaled corticosteroids and enzymatic inhibitors
Daveluy, A., Raignoux, C., Miremont‐Salamé, G., Girodet, P., Moore, N. D., Haramburu, F., & Molimard, M. (2009) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-009-0653-4 · Cited by 47 · cited 1×
“Similarly the inducers/stimulators of this iso-enzyme decrease the plasma steroid levels [52].”
BackgroundRohatagi, S., Krishnaswami, S., Pfister, M., & Sahasranaman, S. (2005) · American Journal of Therapeutics · doi:10.1097/01.mjt.0000155110.69831.75 · Cited by 44
The Role of Nasal Corticosteroids in the Treatment of Rhinitis
Meltzer, E. O. (2011) · Immunology and Allergy Clinics of North America · doi:10.1016/j.iac.2011.05.004 · Cited by 42 · cited 1×
“Intranasal corticosteroids (INC) are the main stay of treatment in patients with Allergic Rhinitis and Chronic Rhino Sinusitis [42, 43].”
BackgroundValin, N., De Castro, N., Garrait, V., Bergeron, A., Bouche, C., & Molina, J. M. (2009) · Journal of the International Association of Physicians in AIDS Care · doi:10.1177/1545109709332019 · Cited by 42 · cited 1×
“In iatrogenic CS, the exogenous steroids suppress HPA axis resulting in decreased production of cortisol.”
BackgroundSobieraj, D. M., WHITE, C., & Coleman, C. I. (2008) · Clinical Therapeutics · doi:10.1016/j.clinthera.2008.08.004 · Cited by 41 · cited 1×
“Use of ICS are associated with increased risk of pneumonia, tuberculosis, easy bruising, osteoporosis, diabetes, oro-pharyngeal candidiasis, hoarseness of voice and even iatrogenic CS in patients with COPD, where the risk-benefit ratio has to be considered before starting steroids [17-24].”
BackgroundExogenous Cushing Syndrome Mimicking Human Immunodeficiency Virus Lipodystrophy
Gupta, S. K., & Dubé, M. P. (2002) · Clinical Infectious Diseases · doi:10.1086/342562 · Cited by 41
Linear growth and body mass index in pediatric patients with Cushing’s disease or simple obesity
Greening, J. E., Storr, H. L., McKenzie, S. A., Davies, K. M., Martin, L., Grossman, A. B., & Savage, M. O. (2006) · Journal of Endocrinological Investigation · doi:10.1007/bf03349191 · Cited by 40 · cited 1×
“Growth failure with associated gain in weight is one of the most important clinical features presents in paediatric CS [76].”
BackgroundAcute Exacerbations of COPD: Identification of Biological Clusters and Their Biomarkers
Bafadhel, M., McKenna, S., Terry, S., Mistry, V., Reid, C., Haldar, P., McCormick, M. J., Haldar, K., Kebadze, T., Duvoix, A., et al. (2011) · Cited by 40
Daniel, E., & Newell-Price, J. D. C. (2013) · Medicine · doi:10.1016/j.mpmed.2013.06.007 · Cited by 37
Wlodarczyk, J. H., Gibson, P. G., & Caeser, M. (2008) · Annals of Allergy Asthma & Immunology · doi:10.1016/s1081-1206(10)60400-0 · Cited by 34 · cited 1×
“Iatrogenic CS is usually associated with evidence of Adrenal insufficiency [98, 99].”
BackgroundPK/PD of inhaled corticosteroids: The risk/benefit of inhaled ciclesonide
Rohatagi, S., Derendorf, H., Zech, K., Nave, R., & Banerji, D. D. (2003) · Journal of Allergy and Clinical Immunology · doi:10.1016/s0091-6749(03)80757-1 · Cited by 32
Kannisto, S., Laatikainen, A., Taivainen, A. H., Savolainen, K., Tukiainen, H. O., & Voutilainen, R. (2004) · European Journal of Endocrinology · doi:10.1530/eje.0.1500687 · Cited by 29
Cushing's syndrome without excess cortisol
Woods, D. R., Arun, C. P., Corris, P. A., & Perros, P. (2006) · BMJ · doi:10.1136/bmj.332.7539.469 · Cited by 21 · cited 1×
“Iatrogenic CS is the most common cause of CS [78].”
BackgroundIntraocular Pressure in Cushing’s Syndrome
Sayegh, F., & Weigelin, E. (2009) · Ophthalmic Research · doi:10.1159/000264775 · Cited by 20 · cited 1×
“Increase in intraocular pressure, posterior sub-capsular cataract and retinal detachment are the ophthalmologic problems in CS [74].”
BackgroundSystemic Disposition and Effects of Inhaled Corticosteroids
(2001) · CRC Press eBooks · doi:10.3109/9780203908532-12 · Cited by 9
Iatrogenic Cushing's syndrome: a different story
Agadi, S. (2003) · The Lancet · doi:10.1016/s0140-6736(03)12811-5 · Cited by 8 · cited 1×
“But some features, such as an increase in intraocular pressure, benign intracranial hypertension, cataracts, osteoporosis, aseptic necrosis of the femoral head, and pancreatitis, are more common in iatrogenic than endogenous CS, whereas features like hypertension, hirsutism, and oligomenorrhea/amenorrhea are less prev…”
BackgroundMeyer, D. O. P. (2013) · Journal of Antivirals & Antiretrovirals · doi:10.4172/jaa.1000086 · Cited by 5
Barnes, P. J. (2005) · Clinical & Experimental Allergy · doi:10.1111/j.1365-2222.2005.02292.x · Cited by 3
John, G., Ollo, D., Meyer, P., Herold, M., Samer, C. F., & Calmy, A. (2013) · Archive ouverte UNIGE (University of Geneva) · Cited by 2
Research works printed but not linked: 5
- Global strategy for asthma management and prevention NHLBI/WHO workshop report March 1993 National Institutes of Health 2002. In: Publication number 95-36-59 issued January. 1995.
- Boezen HM, Schouten JP, Weiss ST. The Dutch hypothesis on chronic nonspecific lung disease. Eur Respir Mon 2000; 15 : 37-47.
- Mutch E, Nave R, Zech K, Williams FM. Esterases involved in the hydrolysis of ciclesonide in human tissues. Eur Respir J 2003; 22 (Suppl 45 ) : S267-8.
- Miller-Larsson A, Axelsson B-O, Brattsand R, Edsbacker S, Ingelf J. Relative lipophilicity of budesonide, fluticasone propionate, mometasone furoate, and ciclesonide.Preference of variable lipophilicity in airways versus systemic compartment [Abstract]. Am J Respir Crit Care Med 2003; 167 : A773.
- Felig P, Frohman L, Chrousos GP, Eds. Glucocorticoid therapy Endocrinology and metabolism. 4th ed New York McGraw-Hill. 2001; pp. 609-32.
Cited by
Glucocorticoid induced adrenal insufficiency
Prete, A., & Bancos, I. (2021) · BMJ · doi:10.1136/bmj.n1380 · Cited by 155
Beuschlein, F., Else, T., Bancos, I., Hahner, S., Hamidi, O., van Hulsteijn, L., Husebye, E. S., Karavitaki, N., Prete, A., Vaidya, A., et al. (2024) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgae250 · Cited by 172
Beuschlein, F., Else, T., Bancos, I., Hahner, S., Hamidi, O., van Hulsteijn, L. T., Husebye, E. S., Karavitaki, N., Prete, A., Vaidya, A., et al. (2024) · European Journal of Endocrinology · doi:10.1093/ejendo/lvae029 · Cited by 155
Turkish Guidelines for Diagnosis and Treatment of Allergic Rhinitis (ART)
Ecevit, M. C., Özcan, M., Can, İ. H., Tatar, E. Ç., Özer, S., Esen, E., Atan, D., Göde, S., Elsürer, Ç., Eryılmaz, A., et al. (2021) · Turkish Archives of Otorhinolaryngology · doi:10.4274/tao.2021.suppl.1 · Cited by 23
Alidoost, M., Conte, G. A., Agarwal, K., Carson, M., Lann, D. E., & Marchesani, D. (2020) · International Medical Case Reports Journal · doi:10.2147/imcrj.s254461 · Cited by 20
Metadata
- Authors
- A.V, R.
- Venue
- The Open Respiratory Medicine Journal
- Publisher
- Bentham Science Publishers Ltd.
- Published
- 2014-12-31
- Volume
- 8
- Issue
- 1
- Pages
- 74-84
- ISSN
- 1874-3064 (ISSN-L)
- PMC
- PMC4319196
- OpenAlex
- W2006492546
- Cited by
- 17
- References
- 104
- Citations by year
- 2026: 1 · 2025: 1 · 2024: 2 · 2022: 3 · 2021: 4 · 2020: 1 · 2019: 1 · 2018: 1 · 2017: 1 · 2016: 1 · 2014: 1
- FWCI
- 0.80
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Locations
- The Open Respiratory Medicine Journal (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adrenal Hormones and Disorders
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Pituitary Gland Disorders and Treatments
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Toxicology › Pharmacovigilance and Adverse Drug Reactions
- Keywords
- iatrogenic Cushing's syndrome, intranasal corticosteroids, asthma, allergic rhinitis, cytochrome P450 inhibitors, adrenal suppression, HPA axis suppression, osteoporosis, intraocular pressure, adrenal crisis, drug interactions
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.


